1. Generics Bulletin
  2. >>Products
  3. >>Generics

Sandoz Sees Market Opening Up In China

 
• By Aidan Fry

As China’s government raises quality standards for generics, Sandoz views the local market as promising, according to the Novartis division’s head, Richard Francis.

GB1812_Invest_182946794_1200.jpg
Sandoz is investing in building an attractive portfolio for the Chinese market • Source: Shutterstock

Sandoz’ home markets in Europe currently represent half of all sales generated by Novartis’ generics division, while the US – where the company is preparing to divest its solid-dose and dermatology operations to Aurobindo – makes up just over a quarter. Nevertheless, the division’s business in Asia, Africa and Australasia generated turnover of just over US$1.0 billion in the first nine months of 2018 , while Sandoz’ total sales in ‘Emerging Growth Markets’ over the same period fell just short of US$2.0 billion.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

BGMA Becomes Medicines UK

 
• By Dave Wallace

The UK generics and biosimilars industry will now be represented by Medicines UK, the new name for the former British Generic Manufacturers Association.

UK Forxiga SPCs Wiped Out As Trio Succeed With Plausibility Attack

 
• By Dean Rudge

Generic competition to AstraZeneca’s blockbuster SGLT2 inhibitor Forxiga (dapagliflozin) treatment for diabetes may hit England and Wales earlier than 2028 after a pair of SPCs were invalidated following proceedings initiated by a trio of generics manufacturers.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.

Glenmark’s UK Dapagliflozin Blocked On Appeal After Teva Readied Launch

 
• By Dean Rudge

Glenmark’s advantage for its UK generic version of AstraZeneca’s Forxiga (dapagliflozin) has quickly been snuffed out, after the originator won on appeal its request for injunctive relief.

More from Products